Latest news
AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead - StocktwitsStocktwits · Fri, 07 Aug 2026 08:57:57 GMTAIM ImmunoTech completes last dose in Phase 2 p... - PluangPluang · Mon, 03 Aug 2026 13:27:47 GMTAIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 12:33:00 GMT